Abstract:5527 Background: Locally advanced cervical squamous cell carcinoma (LACSCC) is associated with poor survival, and elderly patients generally have fewer treatment options due to chemotherapy intolerance. Nimotuzumab is a humanized monoclonal antibody that has demonstrated therapeutic activity in many tumors. We conducted a single-arm trial to investigate the efficacy and safety of combining nimotuzumab and radiotherapy for elderly patients with LACSCC. Methods: In this prospective, multicenter, open-label, and single-arm trial, patients with LACSCC were registered (NCT04976478) and enrolled from Nov 2021 to Jan 2023. All patients were ≥ 65 years old, had ECOG of 0-2, histological diagnosis of cervical squamous cell carcinoma, clinical stage IB3-IVA (FIGO 2018), intolerant to chemotherapy, or refused chemotherapy. The regimen was nimotuzumab (200 mg once in a week for 6 weeks) combined with radiotherapy. The radiotherapy scheme contained intensity-modulated radiotherapy (IMRT)/volumetric intensity-modulated arc therapy (VMAT) with pelvic/extended field irradiation (45-50.4Gy, 1.8-2.0Gy/f, 25-28f), and brachytherapy (HR-CTV D90, 80-85Gy), of which brachytherapy plus external beam radiotherapy was completed in 8 weeks. The primary endpoints were overall survival (OS) and disease-free survival (DFS). Other assessed endpoints were objective response rate (ORR), disease control rate (DCR) and complete response rate (CRR). All adverse events were monitored and recorded. Results: As of Jan 2023, 119 elderly patients have been enrolled and all patients were included in the efficacy and safety analysis. The median follow-up was 16.16 months (95% CI: 13.14-17.45). Nimotuzumab combined with radiotherapy resulted in favorable OS (1 year-OS: 96.03%, 95% CI: 89.75-98.50; 2 year-OS: 90.21%, 95% CI: 78.98-95.60), and DFS (1 year-DFS: 85.71%, 95% CI: 76.98-91.31; 2 year-DFS: 78.31%, 95% CI: 66.67-86.29). The ORR was 89.92%, DCR was 93.28%, and CRR was 52.94%. A total of seven patients died, of which three were due to disease progression and two were of unknown causes. The most common Grade 3-5 adverse events (AEs) mainly included leukopenia (3.36%), anemia (2.52%), and neutropenia (1.68%). None of the patients developed severe AEs or deaths. So far, this trial is still ongoing. Conclusions: Among elderly LACSCC patients, adding nimotuzumab to radiotherapy indicated promising efficacy and appeared to have manageable toxicity. Nimotuzumab plus radiotherapy could represent a novel treatment strategy for this population. Clinical trial information: NCT04976478 .

Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study.

Long-Term Treatment Outcomes of the Elder Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy or Radiotherapy.

Safety and Efficacy Analysis of Chemoradiotherapy/radiotherapy Combined with Nimotuzumab for Treating Unresectable Oesophageal Squamous Cell Carcinoma in Elderly Patients: a Retrospective Analysis

Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial

760P Efficacy and Safety of Nimotuzumab Plus Radiotherapy for Elderly Patients with Locally Advanced Cervical Squamous Cell Carcinoma

Feasibility and efficacy of concurrent chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: a respective study of 116 cases from a single institution.

Nimotuzumab in combination with radiotherapy for elderly patients with locally advanced cervical squamous cell carcinoma: Results from a prospective, multicenter, open-label, single-arm trial.

Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients

The Application of Nimotuzumab Combined With Definitive Chemoradiotherapy Toward the Treatment of Locally Advanced Cervical Esophageal Carcinoma: A Retrospective Study

Feasibility and Efficiency of Concurrent Chemoradiotherapy with Capecitabine and Cisplatin Versus Radiotherapy Alone for Elderly Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: Experience of Two Centers

Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.

Concurrent Radiotherapy with Gefitinib in Elderly Patients with Esophageal Squamous Cell Carcinoma: Preliminary Results of a Phase II Study

Definitive concurrent chemoradiotherapy with S-1 and cisplatin in elderly esophageal squamous cell carcinoma patients.

Comparison of Radiotherapy Alone Versus Concurrent Chemoradiotherapy in the Treatment of Elderly Esophageal Cancer

Does chemoradiotherapy benefit elderly patients with esophageal squamous cell cancer? A propensity-score matched analysis on multicenter data (3JECROG R-03A)

Definitive Chemoradiotherapy with Capecitabine and Cisplatin in Elder Patients with Squamous Cell Esophageal Carcinoma

Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study

Is There A Benefit in Receiving Concurrent Chemoradiotherapy for Elderly Patients with Inoperable Thoracic Esophageal Squamous Cell Carcinoma?

Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial

Concurrent Radiotherapy with Gefitinib in Elderly Patients with Esophageal Squamous Cell Carcinoma: Preliminary Results of a Phase II Study.

Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study).